L26/P-268 Identification of genes associated with embryo quality in advanced maternal age
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.604 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von J. Kim und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Which genes are associated with reduced embryo quality in women of advanced maternal age (AMA) Summary answer Comparative analysis of human 8-cell embryo proteomic datasets by maternal age revealed three genes associated with advanced maternal age- Zc3h13, Dnase2, and Arhgef28 What is known already Advanced maternal age (AMA), typically defined as 35 years or older, is associated with an increased risk of adverse pregnancy outcomes. Women of AMA have higher rates of embryonic aneuploidy and miscarriage, as well as a greater incidence of pregnancy-related maternal complications. Importantly, age-related subfertility cannot be attributed solely to impaired uterine receptivity; declines in oocyte and embryo quality are major contributors to reduced developmental competence and diminished ovarian reserve. Therefore, elucidating the factors and mechanisms by which AMA compromises embryo developmental potential is critical for understanding and addressing age-related infertility. Study design, size, duration Single-embryo proteomic data were re-grouped by maternal age into two cohorts: 20–29 years (n = 58 embryos) and 35–40 years (n = 31 embryos). Differentially expressed proteins (DEPs) were identified by comparing these cohorts with a reference dataset of good-quality embryos (n = 7). The expression patterns of selected DEPs were further assessed using real-time PCR and by cross-referencing proteomic profiles across preimplantation-stage embryos. Three candidate genes were prioritized for functional analyses. Participants/materials, setting, methods Proteomic profiles from a published single-embryo dataset (Zhu et al., 2025, Cell) were re-grouped by maternal age (20–29, n = 58; 35–40, n = 31) and benchmarked against good-quality embryos (n = 7). Differentially expressed proteins were identified by one-way ANOVA (fold-change >1.5, p < 0.05). Candidates were prioritized by functional domains and preimplantation expression patterns (proteomics and RT–qPCR). CRISPR/Cas9 knockout was performed in 1-cell mouse zygotes microinjected with Cas9 mRNA (20 ng/μl) and sgRNA (10 ng/μl) at 20 h post-hCG. Main results and the role of chance To identify molecular factors associated with reduced embryo quality in advanced maternal age (AMA), we first performed a maternal age–stratified re-analysis of published single-embryo proteomic datasets. From the embryo proteomic dataset, we identified 44 AMA-specific differentially expressed proteins (DEPs), including 17 upregulated and 27 downregulated proteins. Protein and transcript abundance of selected DEPs were further evaluated across preimplantation stages using proteomic profiles and RT–qPCR. Based on expression dynamics and domain annotations, three genes (Zc3h13, Dnase2, and Arhgef28) were prioritized for functional analysis. CRISPR/Cas9 knockout was performed by zygote microinjection, and on-target editing was confirmed by single-blastocyst genotyping. High editing efficiencies were achieved for all three genes (>90%; 90%, 100%, and 100%, respectively; n = 10 embryos per gene). Zc3h13 and Dnase2 knockout embryos showed reduced developmental competence, with blastocyst rates of 57.5% and 22.2% at E4.5 compared with Cas9-injected controls (84.8%). Ongoing immunostaining and RT–qPCR analyses are being used to define the mechanisms by which these genes regulate preimplantation development. Collectively, our patient-derived proteomic re-analysis identified AMA-associated candidates and functionally implicated Zc3h13 and Dnase2 as regulators of early embryonic development. Limitations, reasons for caution This study has limitations. Key findings require validation at mRNA and protein levels in independent in vivo models, ideally using embryos from women of advanced maternal age and/or naturally aged mice. Functional validation is ongoing, and species differences between human and mouse experiments may limit direct translation. Wider implications of the findings We aim to identify maternal age–associated biomarkers of embryo quality and elucidate their mechanisms. These insights will support translation to assisted reproductive technologies (ART), including the development of improved embryo assessment strategies and optimized culture media conditions to enhance developmental competence. Trial registration number No
Zitieren
APA
Kim, J., Yoon, S., Youn, C., Lee, H., Kim, B., & Kim, J. (2026). L26/P-268 Identification of genes associated with embryo quality in advanced maternal age. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.604
Vancouver
Kim J, Yoon S, Youn C, Lee H, Kim B, Kim J. L26/P-268 Identification of genes associated with embryo quality in advanced maternal age. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.604
BibTeX
@article{Kim2026,
author = {Kim, J. and Yoon, S. and Youn, C. and Lee, H. and Kim, B.K. and Kim, J.S.},
title = {L26/P-268 Identification of genes associated with embryo quality in advanced maternal age},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.604}
}
EUVIMED